Abstract
MUC16/CA125 is a tumor marker currently used in clinics for the follow-up of patients with ovarian cancer. However, MUC16 expression is not entirely restricted to ovarian malignancies and has been reported in other cancers including breast cancer. Although it is well established as a biomarker, function of MUC16 in cancer remains to be elucidated. In the present study, we investigated the role of MUC16 in breast cancer and its underlying mechanisms. Interestingly, our results showed that MUC16 is overexpressed in breast cancer tissues whereas not expressed in non-neoplastic ducts. Further, stable knockdown of MUC16 in breast cancer cells (MDA MB 231 and HBL100) resulted in significant decrease in the rate of cell growth, tumorigenicity and increased apoptosis. In search of a mechanism for breast cancer cell proliferation we found that MUC16 interacts with the ezrin/radixin/moesin domain-containing protein of Janus kinase (JAK2) as demonstrated by the reciprocal immunoprecipitation method. These interactions mediate phosphorylation of STAT3 (Tyr705), which might be a potential mechanism for MUC16-induced proliferation of breast cancer cells by a subsequent co-transactivation of transcription factor c-Jun. Furthermore, silencing of MUC16 induced G2/M arrest in breast cancer cells through downregulation of Cyclin B1 and decreased phosphorylation of Aurora kinase A. This in turn led to enhanced apoptosis in the MUC16-knockdown breast cancer cells through Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated extrinsic apoptotic pathway with the help of c-Jun N-terminal kinase signaling. Collectively, our results suggest that MUC16 has a dual role in breast cancer cell proliferation by interacting with JAK2 and by inhibiting the apoptotic process through downregulation of TRAIL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bafna S, Singh AP, Moniaux N, Eudy JD, Meza JL, Batra SK . (2008). MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res 68: 9231–9238.
Bast Jr RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB . (1998). CA 125: the past and the future. Int J Biol Markers 13: 179–187.
Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W et al. (2001). SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98: 13681–13686.
Blalock TD, Spurr-Michaud SJ, Tisdale AS, Heimer SR, Gilmore MS, Ramesh V et al. (2007). Functions of MUC16 in corneal epithelial cells. Invest Ophthalmol Vis Sci 48: 4509–4518.
Bode AM, Dong Z . (2007). The functional contrariety of JNK. Mol Carcinog 46: 591–598.
Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N et al. (2003). STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197: 157–168.
Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL et al. (2008). MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res 68: 2065–2070.
Chen M, Cheng A, Chen YQ, Hymel A, Hanson EP, Kimmel L et al. (1997). The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc Natl Acad Sci USA 94: 6910–6915.
Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL et al. (2000). Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 97: 1754–1759.
Clevenger CV . (2004). Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 165: 1449–1460.
Coqueret O . (2003). New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13: 65–70.
Eskes R, Desagher S, Antonsson B, Martinou JC . (2000). Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 20: 929–935.
Fendrick JL, Konishi I, Geary SM, Parmley TH, Quirk Jr JG, O'Brien TJ . (1997). CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line. Tumour Biol 18: 278–289.
Firmbach-Kraft I, Byers M, Shows T, la-Favera R, Krolewski JJ . (1990). tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 5: 1329–1336.
Fujimoto K, Hosotani R, Doi R, Wada M, Lee JU, Koshiba T et al. (1999). Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells. Int J Cancer 81: 637–644.
Gamet-Payrastre L, Li P, Lumeau S, Cassar G, Dupont MA, Chevolleau S et al. (2000). Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 60: 1426–1433.
Ginsberg M, Czeko E, Muller P, Ren Z, Chen X, Darnell Jr JE . (2007). Amino acid residues required for physical and cooperative transcriptional interaction of STAT3 and AP-1 proteins c-Jun and c-Fos. Mol Cell Biol 27: 6300–6308.
Harrison DA, Binari R, Nahreini TS, Gilman M, Perrimon N . (1995). Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J 14: 2857–2865.
Hartwell LH, Weinert TA . (1989). Checkpoints: controls that ensure the order of cell cycle events. Science 246: 629–634.
Hattrup CL, Gendler SJ . (2008). Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol 70: 431–457.
He L, Yang H, Ma Y, Pledger WJ, Cress WD, Cheng JQ . (2008). Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression. J Biol Chem 283: 31012–31020.
Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M et al. (2003). Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 114: 585–598.
Huang LJ, Constantinescu SN, Lodish HF . (2001). The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 8: 1327–1338.
Huang Y, Walstrom A, Zhang L, Zhao Y, Cui M, Ye L et al. (2009). Type I interferons and interferon regulatory factors regulate TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected macrophages. PLoS One 4: e5397.
Jin P, Hardy S, Morgan DO . (1998). Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol 141: 875–885.
Johnson R, Spiegelman B, Hanahan D, Wisdom R . (1996). Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol 16: 4504–4511.
Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A . (2000). Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12: 611–620.
Korgun ET, Celik-Ozenci C, Acar N, Cayli S, Desoye G, Demir R . (2006). Location of cell cycle regulators cyclin B1, cyclin A, PCNA, Ki67 and cell cycle inhibitors p21, p27 and p57 in human first trimester placenta and deciduas. Histochem Cell Biol 125: 615–624.
Kufe DW . (2009). Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 9: 874–885.
LeBlanc HN, Ashkenazi A . (2003). Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66–75.
Lee S, Helfman DM . (2004). Cytoplasmic p21Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK/cofilin pathway. J Biol Chem 279: 1885–1891.
Levy DE, Darnell Jr JE . (2002). Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651–662.
Li G, Gustafson-Brown C, Hanks SK, Nason K, Arbeit JM, Pogliano K et al. (2003). c-Jun is essential for organization of the epidermal leading edge. Dev Cell 4: 865–877.
Lin HH, Chen JH, Huang CC, Wang CJ . (2007). Apoptotic effect of 3,4-dihydroxybenzoic acid on human gastric carcinoma cells involving JNK/p38 MAPK signaling activation. Int J Cancer 120: 2306–2316.
Marumoto T, Hirota T, Morisaki T, Kunitoku N, Zhang D, Ichikawa Y et al. (2002). Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells 7: 1173–1182.
Moritani S, Ichihara S, Hasegawa M, Endo T, Oiwa M, Yoshikawa K et al. (2008). Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? Hum Pathol 39: 666–671.
Munoz-Pinedo C, Guio-Carrion A, Goldstein JC, Fitzgerald P, Newmeyer DD, Green DR . (2006). Different mitochondrial intermembrane space proteins are released during apoptosis in a manner that is coordinately initiated but can vary in duration. Proc Natl Acad Sci USA 103: 11573–11578.
Munro EG, Jain M, Oliva E, Kamal N, Lele SM, Lynch MP et al. (2009). Upregulation of MUC4 in cervical squamous cell carcinoma: pathologic significance. Int J Gynecol Pathol 28: 127–133.
O'Brien TJ, Beard JB, Underwood LJ, Shigemasa K . (2002). The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol 23: 154–169.
Orren DK, Petersen LN, Bohr VA . (1997). Persistent DNA damage inhibits S-phase and G2 progression, and results in apoptosis. Mol Biol Cell 8: 1129–1142.
Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP et al. (2004). BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 279: 19643–19648.
Perez BH, Gipson IK . (2008). Focus on molecules: human mucin MUC16. Exp Eye Res 87: 400–401.
Ponnusamy MP, Lakshmanan I, Jain M, Das S, Chakraborty S, Dey P et al. (2010). MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene 29: 5741–5754.
Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS et al. (2009). TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 113: 217–230.
Rakha EA, Boyce RW, bd El-Rehim D, Kurien T, Green AR, Paish EC et al. (2005). Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 18: 1295–1304.
Sherr CJ . (1996). Cancer cell cycles. Science 274: 1672–1677.
Singh AP, Moniaux N, Chauhan SC, Meza JL, Batra SK . (2004). Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res 64: 622–630.
Singh PK, Wen Y, Swanson BJ, Shanmugam K, Kazlauskas A, Cerny RL et al. (2007). Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res 67: 5201–5210.
Tanaka H, Yamashita T, Asada M, Mizutani S, Yoshikawa H, Tohyama M . (2002). Cytoplasmic p21(Cip1/WAF1) regulates neurite remodeling by inhibiting Rho-kinase activity. J Cell Biol 158: 321–329.
Tong W, Pollard JW . (1999). Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. Mol Cell Biol 19: 2251–2264.
Velazquez L, Fellous M, Stark GR, Pellegrini S . (1992). A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 70: 313–322.
Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ . (1996). BID: a novel BH3 domain-only death agonist. Genes Dev 10: 2859–2869.
Watson CJ . (2001). Stat transcription factors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 6: 115–127.
Wu YM, Nowack DD, Omenn GS, Haab BB . (2009). Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J Proteome Res 8: 1876–1886.
Yin BW, Dnistrian A, Lloyd KO . (2002). Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer 98: 737–740.
Yu H, Pardoll D, Jove R . (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798–809.
Yue P, Turkson J . (2009). Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 18: 45–56.
Zenz R, Scheuch H, Martin P, Frank C, Eferl R, Kenner L et al. (2003). c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell 4: 879–889.
Zhao L, Ma Y, Seemann J, Huang LJ . (2010). A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F). Biochem J 426: 91–98.
Acknowledgements
We are supported by grants from the National Institutes of Health (CA78590, CA111294, CA133774 and CA131944) and Department of Defense (BC101014). We thank Dr Jessica Mercer, Editorial Grants Associate at UNMC, for carefully editing this manuscript. We also acknowledge Erik Moore and Kavita Mallya for their technical support. We also thank Janice A Tayor and James R Talaska of the confocal laser scanning microscope core facility at UNMC for their support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Lakshmanan, I., Ponnusamy, M., Das, S. et al. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene 31, 805–817 (2012). https://doi.org/10.1038/onc.2011.297
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.297
Keywords
This article is cited by
-
MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR
Breast Cancer Research (2023)
-
High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer
Breast Cancer Research and Treatment (2023)
-
Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies
npj Precision Oncology (2023)
-
Mucin 16 Promotes Colorectal Cancer Development and Progression Through Activation of Janus Kinase 2
Digestive Diseases and Sciences (2022)
-
Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma
Oncogene (2022)